1053 related articles for article (PubMed ID: 16219666)
1. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
2. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
3. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
4. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
[TBL] [Abstract][Full Text] [Related]
5. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
6. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
7. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
8. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
9. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1.
Speck M; Cho YM; Asadi A; Rubino F; Kieffer TJ
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E923-32. PubMed ID: 21304061
[TBL] [Abstract][Full Text] [Related]
10. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
[TBL] [Abstract][Full Text] [Related]
11. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
12. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
Nauck MA; Holst JJ; Willms B; Schmiegel W
Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
[TBL] [Abstract][Full Text] [Related]
14. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
[TBL] [Abstract][Full Text] [Related]
15. What do we know about the secretion and degradation of incretin hormones?
Deacon CF
Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
[TBL] [Abstract][Full Text] [Related]
16. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
17. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
[TBL] [Abstract][Full Text] [Related]
18. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
19. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
20. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery.
Patriti A; Facchiano E; Sanna A; Gullà N; Donini A
Obes Surg; 2004; 14(6):840-8. PubMed ID: 15318993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
